Answers are grounded in this paper and cite their sources.
Participants were positive about ctDNA monitoring and early treatment and would welcome extra surveillance, as well as trust ctDNA tests. This indicates the feasibility of the wider implementation of ctDNA tests, which have applicability for many tumour types and disease stages.
No takes yet. Share an insight, caveat, or question.
Woof et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: